{"id":"intravenous-busulfan","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL820","moleculeType":"Small molecule","molecularWeight":"246.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Busulfan works by adding an alkyl group to the DNA of cancer cells, which damages the cells' ability to replicate and ultimately leads to cell death. This mechanism is particularly effective against rapidly dividing cells, such as those found in leukemia. As a result, busulfan is often used in chemotherapy regimens to treat various types of cancer.","oneSentence":"Intravenous busulfan is an alkylating agent that interferes with DNA replication, leading to cell death in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:43.533Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML)"}]},"trialDetails":[{"nctId":"NCT05951205","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype","status":"WITHDRAWN","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2027-07-31","conditions":"Sickle Cell Disease","enrollment":""},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT05477563","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-08-02","conditions":"Beta-Thalassemia, Thalassemia, Hematologic Diseases","enrollment":26},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT03392987","phase":"PHASE2","title":"A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)","status":"COMPLETED","sponsor":"Orchard Therapeutics","startDate":"2018-01-25","conditions":"Lysosomal Storage Disease, Metachromatic Leukodystrophy","enrollment":10},{"nctId":"NCT05329649","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-02","conditions":"Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance","enrollment":13},{"nctId":"NCT05356195","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-03","conditions":"Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn","enrollment":16},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT06149403","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orchard Therapeutics","startDate":"2023-12-11","conditions":"MPS-IH (Hurler Syndrome)","enrollment":41},{"nctId":"NCT06506461","phase":"PHASE1","title":"Gene Editing For Sickle Cell Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-03-21","conditions":"Sickle Cell Disease","enrollment":25},{"nctId":"NCT02143830","phase":"PHASE2","title":"HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-04","conditions":"Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS)","enrollment":70},{"nctId":"NCT03016806","phase":"","title":"Umbilical Cord Blood Transplantation From Unrelated Donors","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2015-06","conditions":"Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder","enrollment":30},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT03653247","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Sangamo Therapeutics","startDate":"2019-03-06","conditions":"Sickle Cell Disease","enrollment":7},{"nctId":"NCT00357565","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-11","conditions":"Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission","enrollment":34},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT07074470","phase":"NA","title":"Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-02","conditions":"Primary Central Nervous System Lymphoma (PCNSL)","enrollment":40},{"nctId":"NCT07059741","phase":"NA","title":"Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-10","conditions":"Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)","enrollment":20},{"nctId":"NCT03597594","phase":"PHASE1, PHASE2","title":"Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-09-02","conditions":"Severe Combined Immunodeficiency","enrollment":4},{"nctId":"NCT01985061","phase":"PHASE2","title":"Evaluation of 3 Different Doses of IV Busulfan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2013-12","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":177},{"nctId":"NCT06559176","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prime Medicine, Inc.","startDate":"2024-10-17","conditions":"Chronic Granulomatous Disease, Granulomatous Disease, Chronic","enrollment":12},{"nctId":"NCT05711732","phase":"","title":"Busulfan Sample Collection Study","status":"RECRUITING","sponsor":"Saladax Biomedical, Inc.","startDate":"2024-02-08","conditions":"Subjects Treated With Busulfan","enrollment":150},{"nctId":"NCT05444894","phase":"PHASE1, PHASE2","title":"EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Editas Medicine, Inc.","startDate":"2022-04-29","conditions":"Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major","enrollment":9},{"nctId":"NCT06879847","phase":"NA","title":"A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT01050036","phase":"NA","title":"Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-01-11","conditions":"Leukemia, Myeloid","enrollment":20},{"nctId":"NCT06548958","phase":"NA","title":"A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":"Malignant Hematological Diseases","enrollment":40},{"nctId":"NCT06280378","phase":"PHASE1, PHASE2","title":"Β-Thalassemia Treatment with KL003 Cell Injection","status":"RECRUITING","sponsor":"Kanglin Biotechnology (Hangzhou) Co., Ltd.","startDate":"2024-04-05","conditions":"Transfusion-dependent Beta-Thalassemia","enrollment":41},{"nctId":"NCT04853576","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Editas Medicine, Inc.","startDate":"2021-05-04","conditions":"Sickle Cell Disease, Hemoglobinopathies","enrollment":45},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT06673459","phase":"PHASE3","title":"BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation","enrollment":430},{"nctId":"NCT01639690","phase":"PHASE1","title":"ß-Thalassemia Major with Autologous CD34+ Hematopoietic Progenitor Cells Transduced with TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene","status":"ACTIVE_NOT_RECRUITING","sponsor":"San Rocco Therapeutics","startDate":"2012-07","conditions":"Confirmed Diagnosis of ß-thalassemia Major","enrollment":10},{"nctId":"NCT06613035","phase":"PHASE3","title":"Twice-per-weekSelinexor, 2 Days Melphalan","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-09-30","conditions":"Acute Myeloid Leukemia","enrollment":126},{"nctId":"NCT05569512","phase":"PHASE1","title":"Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML","status":"TERMINATED","sponsor":"Malika Kapadia","startDate":"2022-10-06","conditions":"Acute Myeloid Leukemia, Pediatric Cancer","enrollment":1},{"nctId":"NCT06107400","phase":"EARLY_PHASE1","title":"Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease","status":"RECRUITING","sponsor":"The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army","startDate":"2023-10-08","conditions":"Alpha Thalassemia Hemoglobin H Constant Spring, Hemoglobinopathies, Hereditary Diseases","enrollment":5},{"nctId":"NCT02025881","phase":"PHASE1, PHASE2","title":"Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2013-09-14","conditions":"High-risk Medulloblastoma","enrollment":29},{"nctId":"NCT03852498","phase":"PHASE3","title":"A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)","status":"COMPLETED","sponsor":"Genetix Biotherapeutics Inc.","startDate":"2019-01-24","conditions":"Cerebral Adrenoleukodystrophy (CALD)","enrollment":35},{"nctId":"NCT01033552","phase":"PHASE1, PHASE2","title":"Biochemical Correction of Severe EB by Allo HSCT and \"Off-the-shelf\" MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2010-01","conditions":"Epidermolysis Bullosa","enrollment":32},{"nctId":"NCT00630565","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-07-26","conditions":"Leukemia","enrollment":12},{"nctId":"NCT00540995","phase":"PHASE1, PHASE2","title":"Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2007-06-11","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":25},{"nctId":"NCT03601286","phase":"PHASE1","title":"Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency","status":"RECRUITING","sponsor":"Great Ormond Street Hospital for Children NHS Foundation Trust","startDate":"2018-12-21","conditions":"Severe Combined Immunodeficiency, X-Linked","enrollment":5},{"nctId":"NCT01203020","phase":"PHASE2","title":"Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation","status":"COMPLETED","sponsor":"West Virginia University","startDate":"2010-10-12","conditions":"Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":22},{"nctId":"NCT02906202","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype","status":"COMPLETED","sponsor":"Genetix Biotherapeutics Inc.","startDate":"2016-08-08","conditions":"Beta-Thalassemia","enrollment":24},{"nctId":"NCT00049517","phase":"PHASE3","title":"Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2002-12-19","conditions":"Leukemia","enrollment":657},{"nctId":"NCT04217278","phase":"PHASE2, PHASE3","title":"A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2020-01-27","conditions":"Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome","enrollment":333},{"nctId":"NCT05762510","phase":"EARLY_PHASE1","title":"A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2023-02-22","conditions":"Transfusion Dependent Beta-Thalassemia","enrollment":5},{"nctId":"NCT04067180","phase":"NA","title":"Randomized Clinical Study Assessing Haplo vs. URD in AML","status":"TERMINATED","sponsor":"Karolinska Institutet","startDate":"2019-11-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT01191957","phase":"PHASE3","title":"Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML","status":"COMPLETED","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2008-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":252},{"nctId":"NCT05598593","phase":"PHASE2","title":"Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-23","conditions":"Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma","enrollment":70},{"nctId":"NCT01702831","phase":"PHASE2","title":"Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-10-01","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT02859402","phase":"PHASE2","title":"Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas","status":"RECRUITING","sponsor":"Keimyung University Dongsan Medical Center","startDate":"2016-12","conditions":"T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell","enrollment":34},{"nctId":"NCT01773395","phase":"PHASE2","title":"GVAX vs. Placebo for MDS/AML After Allo HSCT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01-08","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":123},{"nctId":"NCT02151526","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease","status":"COMPLETED","sponsor":"Genetix Biotherapeutics Inc.","startDate":"2013-06-07","conditions":"Beta-Thalassemia Major, Sickle Cell Disease","enrollment":7},{"nctId":"NCT03600909","phase":"PHASE2","title":"A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-15","conditions":"Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)","enrollment":3},{"nctId":"NCT01683123","phase":"","title":"Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT","status":"COMPLETED","sponsor":"Grupo Espanol de trasplantes hematopoyeticos y terapia celular","startDate":"2007-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":143},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256},{"nctId":"NCT01498016","phase":"PHASE2","title":"Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-11","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT02549586","phase":"PHASE2","title":"Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance","status":"COMPLETED","sponsor":"Gary A Levy, O. Ont. MD. FRCP AGAF","startDate":"2015-12","conditions":"Complication of Transplanted Organ, Nos","enrollment":5},{"nctId":"NCT01685411","phase":"NA","title":"Busulfan and Cyclophosphamide Followed By ALLO BMT","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT01338987","phase":"PHASE2","title":"Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-04-19","conditions":"Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia","enrollment":76},{"nctId":"NCT04786002","phase":"","title":"Target Busulfan Exposure in Children With HSCT in China","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-11-01","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":500},{"nctId":"NCT00469014","phase":"PHASE2","title":"Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia","enrollment":72},{"nctId":"NCT00176930","phase":"NA","title":"Stem Cell Transplant for Hematological Malignancy","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2001-10","conditions":"Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute","enrollment":330},{"nctId":"NCT02544425","phase":"PHASE2","title":"VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-02-21","conditions":"Extranodal NK-T-Cell Lymphoma","enrollment":27},{"nctId":"NCT01605032","phase":"PHASE2","title":"Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-02","conditions":"DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma","enrollment":19},{"nctId":"NCT01734850","phase":"PHASE1, PHASE2","title":"Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection","status":"COMPLETED","sponsor":"Calimmune, Inc.","startDate":"2013-04","conditions":"Human Immunodeficiency Virus","enrollment":13},{"nctId":"NCT00836628","phase":"PHASE1","title":"Study of Busulfan for Refractory Central Nervous System (CNS) Tumors","status":"WITHDRAWN","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2008-07","conditions":"Refractory Brain Tumors","enrollment":""},{"nctId":"NCT00822393","phase":"PHASE3","title":"Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2008-11-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":570},{"nctId":"NCT01413178","phase":"PHASE3","title":"A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-09-30","conditions":"Myeloma","enrollment":205},{"nctId":"NCT00176852","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Hemoglobinopathy","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-06","conditions":"Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia","enrollment":22},{"nctId":"NCT03339700","phase":"PHASE2","title":"Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2018-09-15","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":15},{"nctId":"NCT02605460","phase":"PHASE2","title":"Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2014-02","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia","enrollment":20},{"nctId":"NCT03315078","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency","status":"UNKNOWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"X-Linked Combined Immunodeficiency Diseases","enrollment":13},{"nctId":"NCT00997386","phase":"PHASE2","title":"Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2009-09","conditions":"Hematologic Neoplasms, Multiple Myeloma, Anemia, Aplastic","enrollment":16},{"nctId":"NCT00179764","phase":"NA","title":"Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2000-03-10","conditions":"Tumors, Malignant Melanoma, Hematological Malignancies","enrollment":68},{"nctId":"NCT00801931","phase":"PHASE1, PHASE2","title":"Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders","status":"TERMINATED","sponsor":"Columbia University","startDate":"2007-09-06","conditions":"Leukemia, Lymphoma, Neuroblastoma","enrollment":1},{"nctId":"NCT00943319","phase":"PHASE1, PHASE2","title":"Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-03","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":50},{"nctId":"NCT02483325","phase":"PHASE2","title":"Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2014-09","conditions":"Hematological Diseases","enrollment":33},{"nctId":"NCT03792815","phase":"PHASE2","title":"Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2009-10","conditions":"Non-Hodgkin's Lymphoma","enrollment":51},{"nctId":"NCT01422603","phase":"PHASE1, PHASE2","title":"Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2011-02","conditions":"Acute Myeloid Leukaemia, Myelodysplasia","enrollment":9},{"nctId":"NCT01572181","phase":"PHASE2","title":"Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-04","conditions":"Hematologic Malignancy","enrollment":50},{"nctId":"NCT01043640","phase":"PHASE2","title":"Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2009-12","conditions":"Mucopolysaccharidosis, Hurler Syndrome, Hunter Syndrome","enrollment":46},{"nctId":"NCT00445744","phase":"NA","title":"Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-12","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":52},{"nctId":"NCT00623077","phase":"PHASE1","title":"MT2004-30: Tomotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08","conditions":"Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer","enrollment":23},{"nctId":"NCT00003926","phase":"PHASE1","title":"Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"1998-11","conditions":"Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma","enrollment":13},{"nctId":"NCT00113919","phase":"PHASE1, PHASE2","title":"UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2004-06","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT00238433","phase":"PHASE2","title":"Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-03","conditions":"Lymphoma","enrollment":37},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT01048827","phase":"PHASE1","title":"Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-11","conditions":"Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT03246178","phase":"NA","title":"Haploidentical Transplantation in Severe Aplastic Anemia","status":"UNKNOWN","sponsor":"Wu Xiaoxiong","startDate":"2017-07-10","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT00448357","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":54},{"nctId":"NCT00513474","phase":"PHASE1","title":"Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-01","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":46},{"nctId":"NCT00914849","phase":"PHASE2","title":"Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-08","conditions":"Hematologic Neoplasms","enrollment":68},{"nctId":"NCT00363467","phase":"NA","title":"Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2006-05","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3},{"nctId":"NCT01181271","phase":"PHASE2","title":"Tandem Auto-Allo Transplant for Lymphoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-08","conditions":"Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma","enrollment":42},{"nctId":"NCT02512679","phase":"PHASE2","title":"Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells","status":"TERMINATED","sponsor":"Children's Hospital Los Angeles","startDate":"2007-02","conditions":"Stem Cell Transplantation, Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation","enrollment":20},{"nctId":"NCT02084563","phase":"PHASE2","title":"Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2012-10","conditions":"Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes","enrollment":455},{"nctId":"NCT00410982","phase":"PHASE1","title":"Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":145},{"nctId":"NCT01390402","phase":"PHASE2","title":"Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-01","conditions":"Leukemia, Chronic Myelogenous Leukemia","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":309,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"intravenous busulfan","genericName":"intravenous busulfan","companyName":"Alberta Health services","companyId":"alberta-health-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous busulfan is a small molecule DNA inhibitor used in the treatment of various conditions, including Acute Myeloid Leukemia, Malignant Hematological Diseases, and Myeloproliferative Disorders. It is administered as part of allogeneic stem cell transplantation regimens, including those using haplo-identical family donor grafts and matched unrelated donor grafts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}